Link Between Alzheimer's and Vascular Dementia Holds Promise

October 1999
Worldwide Biotech;Oct99, Vol. 11 Issue 10, p2
Trade Publication
Reports that medications are being studied that are designed to treat Alzheimer's disease and vascular dementia and thus could help simplify the treatment of so-called `mixed dementia.' Cause of mixed dementia; Results of clinical trials of propentofylline that involved patients with vascular dementia; Costs of dementia.


Related Articles

  • Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Hossain, M.; Jhee, S.S.; Shiovitz, T.; McDonald, C.; Sedek, G.; Pommier, F.; Cutler, N.R.; Hossain, Mohammad; Jhee, Stanford S; Shiovitz, Thomas; McDonald, Craig; Sedek, Greg; Pommier, Francoise; Cutler, Neal R // Clinical Pharmacokinetics;2002, Vol. 41 Issue 3, p225 

    Objective: To investigate the bioavailability of rivastigmine, an approved therapy for patients with mild to moderate dementia of the Alzheimer's type, at the highest approved single dose of 6 mg.Design and Setting: Randomised, two-period crossover, single-centre,...

  • Cure for Alzheimer's by 2025? O'Connor, John // McKnight's Long-Term Care News;Apr2012, Vol. 33 Issue 4, p3 

    The article presents information on National Alzheimer's Plan which will cure dementia and Alzheimer's disease in the U.S. by 2025.

  • BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimer's Disease Therapies. Vassar, Robert // Current Medicinal Chemistry - Immunology, Endocrine & Metabolic ;Mar2003, Vol. 3 Issue 1, p47 

    A large (and still growing) body of evidence suggests that the �-amyloid peptide (A�) is central to the pathophysiology of Alzheimer's Disease (AD) and may in fact initiate disease processes that lead to this intractable neurodegenerative disorder. Amyloid plaques composed of A�...

  • The Medicinal Metallochemistry of Alzheimer's Disease. Cherny, Robert A.; Masters, Colin L.; Bush, Ashley I. // Current Medicinal Chemistry - Immunology, Endocrine & Metabolic ;Mar2003, Vol. 3 Issue 1, p9 

    The brain is an organ which is at once enriched in transition metals and highly susceptible to oxidative stress. By virtue of its high affinity for copper the Alzheimer's amyloid protein (A�) is capable of catalytic generation of neurotoxic H2O2 while its aggregation and deposition are...

  • Caring for Persons With Dementia: A Palliative Approach. Panke, Jo Ann; Volicer, Ladislav // Approach: The Naval Safety Center's Aviation Magazine;July-Sep2002, Vol. 47 Issue 7, p143 

    Describes a palliative approach to caring patients with Alzheimer's disease and other progressive dementias. Treatment preferences or advanced directives; Treatment options; Elimination of inappropriate aggressive medical interventions; Intensive therapeutic intervensions; Pain management;...

  • PREVENTING COGNITIVE DECLINE WITH GPC. Kiefer, Dale // Life Extension;Jul2003, Vol. 9 Issue 7, p26 

    Reports on the effectiveness and safety of L-alpha glycerylphosphorylcholine in preventing full-blown dementia of Alzheimer's disease of vascular dementia. Potential therapeutic benefits of natural acetylcholine precursor compounds; Changes in aging brains; Measures of cognitive function.

  • Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. Rosler, Michael // BMJ: British Medical Journal (International Edition);03/06/99, Vol. 318 Issue 7184, p633 

    Evaluates the effects of rivastigmine on the core domains of Alzheimer's disease (AD). Cognitive subscale of the AD assessment scale; Effects on activities of daily living; Tolerability and safety.

  • Better Access To Dementia Drugs.  // Australian Journal of Pharmacy;Jun2013, Vol. 94 Issue 1117, p22 

    The article focuses on changes brought by the Pharmaceutical Benefits Scheme (PBS) as per which, for Alzheimer disease several drugs were approved including rivastigmine, galantamine and memantine, and informs that the Australian government has deducted price of anti-dementia drugs.

  • MINDFULNESS BASED STIMULATION FOR ELDERLY PEOPLE WITH ALZHEIMER'S DISEASE OR OTHER TYPES OF DEMENTIA. Quintana Hernández, Domingo Jesús; Miró Barrachina, María Teresa // Papeles del Psicólogo;sep-dic2015, Vol. 36 Issue 3, p207 

    Psychological treatments are a common practice in healthcare centres for elderly dependent people. Recently, mindfulness practice is being introduced in these settings. However, it is difficult to carry out mindfulness practice in residential or day care centres due to the cognitive impairment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics